The effect of LB as a postoperative analgesic agent for the management of pain in comparison to SB in 100 patients, 50 in each group. LB provided a longer duration of analgesia than SB with a duration being 24.5 ± 6.4 hours, which was statistically different from the SB with a duration of analgesia being 8.3 ± 2.1 hours (p<0.001). LB patients also had lower total pain scores, 24h 4.2 and 48h 3.2 compared with 6.1 and 5.3 of the control group (p=0.03 and p=0.01 respectively). The measure of cumulative opioid use for the LB group was significantly less than that of the control group in 48 hours of consuming 32 mg morphine equivalent as compared to 62 mg morphine equivalent given to the control group with p= 0.02. Endemic adverse events such as nausea, vomiting, and constipation were manifested at a similar frequency between the groups. No statistical difference was also observed regarding the serious adverse events between the 2 groups. In conclusion, LB results in significantly longer analgesic duration with decreased severity, opioid consumption less than SB during the first 48 hours after surgery, and a similar adverse event profile.